6533b837fe1ef96bd12a2892

RESEARCH PRODUCT

Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab

Francesco PassigliaMichele AietaMarco ImperatoriGiovanni MansuetoMarco RussanoAlfredo BerrutiGiulia PasquiniDaniele SantiniElisa RocaTindara FranchinaLorenzo CalvettiAntonio GalvanoAnna Maria Di GiacomoIacopo FioroniGiuseppe AprileDaniela IaconoAlessio CortelliniSandro BarniOlga MartelliLuana CalabròMichele MaioAlain GelibterMaria Rita MigliorinoBruno VincenziAlessandro RussoCorrado FicorellaOlga VendittiSilvia QuadriniSalvatore IntagliataEnrico VasileGiuseppe ToniniFausto PetrelliVincenzo AdamoAlfredo FalconeMario OcchipintiAntonio RussoAndrea NapolitanoFrancesco Pantano

subject

0301 basic medicineOncologyAdultMalemedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentClinical BiochemistryKaplan-Meier EstimateDisease-Free SurvivalDrug Administration ScheduleNO03 medical and health sciences0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungDrug DiscoverymedicineMalignant pleural effusionHumansimmunotherapy; malignant pleural effusion; nivolumab; non-small-cell lung cancerIn patientmalignant pleural effusionLung cancerImmune Checkpoint InhibitorsRetrospective StudiesPharmacologynivolumabbusiness.industryBrain NeoplasmsLiver NeoplasmsImmunotherapymedicine.diseasePrognosisPleural Effusion Malignantrespiratory tract diseases030104 developmental biologyTreatment Outcomenon-small-cell lung cancer030220 oncology & carcinogenesisFemalesense organsNon small cellimmunotherapyNivolumabbusiness

description

Background: Immune-checkpoint inhibitors have radically changed the treatment landscape of Non-Small-Cell Lung Cancer (NSCLC). It is still unclear whether specific clinical characteristics might identify those patients benefiting from immunotherapy more than others. The aim of this study was to identify clinical characteristics associated with disease-specific survival (DSS), time-to-treatment failure (TTF), objective responses (OR) and progressive disease (PD) in NSCLC patients treated with Nivolumab. Methods: This was a multicenter retrospective study conducted on 294 patients treated with Nivolumab for advanced NSCLC. Results: Of the more than 50 variables analyzed, five showed a significant correlation with DSS: ECOG PS, size of the biggest brain metastasis, number of metastatic sites, toxicity, and malignant pleural effusion. Three variables significantly correlated with TTF: malignant pleural effusion, number of metastatic sites, number of liver metastases. Malignant pleural effusion was the only variable showing a significant correlation with OR, as well as the only one correlating with all the endpoints of the study. Conclusions: This study identified clinical characteristics associated with survival and response during treatment with Nivolumab in NSCLC patients. The unfavorable association between malignant pleural effusion and objective response is a novel finding with important translational implications.

yearjournalcountryeditionlanguage
2020-02-06
10.1080/14712598.2020.1724953http://hdl.handle.net/11573/1484803